Clinical characteristics of all patients. Values are median (interquartile range) or mean ± SD unless otherwise specified.
| Variables | All Patients, n = 146 |
|---|---|
| Male, n (%) | 90 (61.6) |
| Age, yrs | 49.4 ± 10.2 |
| PsA characteristics | |
| PsA disease duration, yrs | 7.0 (3.2–13.0) |
| Tender joint count, 0–68 | 3 (0–7) |
| Swollen joint count, 0–66 | 1 (0–2) |
| Damaged joint count, 0–68 | 2 (0–5) |
| VAS pain, 0–100 | 40 (20–60) |
| PtGA, 0–100 | 50 (30–60) |
| PGA, 0–100 | 20 (10–40) |
| PASI, 0–72 | 3.5 (1.0–8.6) |
| HAQ, 0–3 | 0.38 (0–0.88) |
| ESR, mm/h | 22 (11–37) |
| CRP, mg/dl | 0.4 (0.2–1.2) |
| DAPSA, 0–164 | 14.9 (9.0–21.2) |
| PsA medication, n (%) | |
| NSAID | 71 (49.0) |
| Steroid | 10 (6.9) |
| Synthetic DMARD | 68 (46.9) |
| Biologic DMARD | 10 (6.9) |
| CV risk factors | |
| BMI, kg/m2 | 26.1 ± 4.9 |
| Ever smoker, n (%) | 42 (28.8) |
| Systolic BP, mmHg | 132 ± 21 |
| Diastolic BP, mmHg | 82 ± 12 |
| Total cholesterol, mmol/l | 5.1 ± 0.9 |
| HDL cholesterol, mmol/l | 1.5 ± 0.5 |
| LDL cholesterol, mmol/l | 3.0 ± 0.8 |
| Triglycerides, mmol/l | 1.5 ± 0.9 |
| Fasting glucose, mmol/l | 5.4 ± 1.2 |
| Hypertension, n (%) | 64 (43.8) |
| Diabetes, n (%) | 19 (13.0) |
| Dyslipidemia, n (%) | 17 (11.6) |
| CV risk scores*, n (%) | |
| FRS | 5.0 (1.6–12.0) |
| QRISK2 | 3.8 (1.6–8.5) |
| SCORE | 1 (0–1) |
| ASCVD | 4.4 (1.9–9.8) |
↵* Available in 142, 137, 128, and 118 patients for FRS, QRISK2, SCORE, and ASCVD, respectively. PsA: psoriatic arthritis; VAS: visual analog scale; PtGA: patient’s global assessment; PGA: physician’s global assessment; PASI: Psoriasis Area and Severity Index; HAQ: Health Assessment Questionnaire; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAPSA: Disease Activity Index for Psoriatic Arthritis; NSAID: nonsteroidal antiinflammatory drugs; DMARD: disease-modifying antirheumatic drugs; CV: cardiovascular; BMI: body mass index; BP: blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; FRS: Framingham risk score; SCORE: Systematic COronary Risk Evaluation; ASCVD: atherosclerotic cardiovascular disease risk algorithm.